Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8246958
APP PUB NO 20100081793A1
SERIAL NO

12175116

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • BIOGEN MA INC.;ELAN PHARMACEUTICALS, INC.;ATHENA NEUROSCIENCES, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bendig, Mary M Villanova, US 12 668
Jones, Tarran S Radlett, GB 4 67
Leger, Olivier J Hertfordshire, GB 5 208
Saldanha, Jose Enfield, GB 27 1072
Yednock, Ted A Fairfax, US 8 408

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 21, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00